The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
The news sent Isis's shares up 9 percent in trade on Monday. Biogen Idec stock was last roughly flat.
The deal is the fourth between the companies in the last two years, and aims to use the "antisense" technology invented by Isis to accelerate discovery of drug targets for neurodegenerative diseases.
Biogen has the option of using the research to develop either antisense drugs, traditional small molecule drugs or antibody-based compounds.
(Read more: The Expedia of Obamacare: Health start-up success)
Antisense drugs aim to interfere at the genetic level to prevent the formation of disease-causing proteins.
"This is a more expansive collaboration in which we will work together over the next several years to use the Isis technology to probe the biology of a disease, develop drug targets and then potentially take those molecules forward," Biogen Chief Executive Officer George Scangos said in a telephone interview.
Biogen is a leader in the market for drugs to treat multiple sclerosis, a progressive neurological disease that can lead to paralysis.
Biogen and Isis are already working to develop an experimental treatment for spinal muscular atrophy which is set to enter late-stage testing in humans. Earlier collaboration has also resulted in an experimental drug for myotonic dystrophy that will soon begin development.
(Read more: Health savings accounts: An $18 billion honey pot)
By next year the companies expect to have drug candidates for three other targets, said Isis CEO Stanley Crooke.
"With the efficiency of antisense we believe we should have a drug moving forward pretty much every year," he said.
(Read more: Time Warner in big health care change)
Crooke said the first focus of the new collaboration with Biogen will likely be neurodegenerative disorders, particularly those involved with motor dysfunction.
He put the potential value of the deal for Isis at "several billion dollars," noting that royalty payments for any eventual antisense drugs would be in the double digit percentages, with smaller payments for non-antisense compounds.